NEW YORK (GenomeWeb) – Chinese firm MedCDx and US-based Admera Health said today that they have entered a non-exclusive collaboration agreement to gain access to each other's existing portfolios and codevelop new companion diagnostics.
MedCDx's offerings include genomics, proteomics, cytology, and pathology solutions. Admera operates a reference laboratory specializing in next-generation molecular diagnostics, providing assays for pharmacogenomics, tumor profiling, and inherited cardiovascular disorders. The firm also provides genomics and bioinformatics services to customers wishing to conduct research in a CLIA environment.
Admera President and CEO Guanghui Hu said in a statement that in addition to supporting development of new companion diagnostics, the geographic position of the two partners will also offer opportunities to "expand clinical trials … in both China and the United States."
Additional terms of the agreement were not disclosed.